NEFL and myeloid sarcoma: Furthermore, NfL has been shown to be a more reliable biomarker for predicting disease progression in progressive forms of MS compared to conventional MRI parameters, such as T2 lesion load or the presence of gadolinium-enhancing lesions [3].